Literature DB >> 36131042

A primary hierarchically organized patient-derived model enables in depth interrogation of stemness driven by the coding and non-coding genome.

Héléna Boutzen1, Seyed Ali Madani Tonekaboni2, Michelle Chan-Seng-Yue1,3, Alex Murison1, Naoya Takayama1,4, Nathan Mbong1, Elvin Wagenblast1, Elias Orouji5, Andrea Arruda1,6, Amanda Mitchell1, Faiyaz Notta1,3, Mark D Minden1,6,7, Mathieu Lupien1,2,8, Kerstin B Kaufmann1, John E Dick9,10.   

Abstract

Many cancers are organized as cellular hierarchies sustained by cancer stem cells (CSC), whose eradication is crucial for achieving long-term remission. Difficulties to isolate and undertake in vitro and in vivo experimental studies of rare CSC under conditions that preserve their original properties currently constitute a bottleneck for identifying molecular mechanisms involving coding and non-coding genomic regions that govern stemness. We focussed on acute myeloid leukemia (AML) as a paradigm of the CSC model and developed a patient-derived system termed OCI-AML22 that recapitulates the cellular hierarchy driven by leukemia stem cells (LSC). Through classical flow sorting and functional analyses, we established that a single phenotypic population is highly enriched for LSC. The LSC fraction can be easily isolated and serially expanded in culture or in xenografts while faithfully recapitulating functional, transcriptional and epigenetic features of primary LSCs. A novel non-coding regulatory element was identified with a new computational approach using functionally validated primary AML LSC fractions and its role in LSC stemness validated through efficient CRISPR editing using methods optimized for OCI-AML22 LSC. Collectively, OCI-AML22 constitutes a valuable resource to uncover mechanisms governing CSC driven malignancies.
© 2022. The Author(s).

Entities:  

Year:  2022        PMID: 36131042     DOI: 10.1038/s41375-022-01697-9

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   12.883


  38 in total

1.  Genomic landscapes and clonality of de novo AML.

Authors:  John Brewin; Gillian Horne; Timothy Chevassut
Journal:  N Engl J Med       Date:  2013-10-10       Impact factor: 91.245

2.  Genomic Classification and Prognosis in Acute Myeloid Leukemia.

Authors:  Elli Papaemmanuil; Moritz Gerstung; Hartmut Döhner; Peter J Campbell; Lars Bullinger; Verena I Gaidzik; Peter Paschka; Nicola D Roberts; Nicola E Potter; Michael Heuser; Felicitas Thol; Niccolo Bolli; Gunes Gundem; Peter Van Loo; Inigo Martincorena; Peter Ganly; Laura Mudie; Stuart McLaren; Sarah O'Meara; Keiran Raine; David R Jones; Jon W Teague; Adam P Butler; Mel F Greaves; Arnold Ganser; Konstanze Döhner; Richard F Schlenk
Journal:  N Engl J Med       Date:  2016-06-09       Impact factor: 91.245

3.  A 17-gene stemness score for rapid determination of risk in acute leukaemia.

Authors:  Stanley W K Ng; Amanda Mitchell; James A Kennedy; Weihsu C Chen; Jessica McLeod; Narmin Ibrahimova; Andrea Arruda; Andreea Popescu; Vikas Gupta; Aaron D Schimmer; Andre C Schuh; Karen W Yee; Lars Bullinger; Tobias Herold; Dennis Görlich; Thomas Büchner; Wolfgang Hiddemann; Wolfgang E Berdel; Bernhard Wörmann; Meyling Cheok; Claude Preudhomme; Herve Dombret; Klaus Metzeler; Christian Buske; Bob Löwenberg; Peter J M Valk; Peter W Zandstra; Mark D Minden; John E Dick; Jean C Y Wang
Journal:  Nature       Date:  2016-12-07       Impact factor: 49.962

4.  Nicotinamide Metabolism Mediates Resistance to Venetoclax in Relapsed Acute Myeloid Leukemia Stem Cells.

Authors:  Courtney L Jones; Brett M Stevens; Daniel A Pollyea; Rachel Culp-Hill; Julie A Reisz; Travis Nemkov; Sarah Gehrke; Fabia Gamboni; Anna Krug; Amanda Winters; Shanshan Pei; Annika Gustafson; Haobin Ye; Anagha Inguva; Maria Amaya; Mohammad Minhajuddin; Diana Abbott; Michael W Becker; James DeGregori; Clayton A Smith; Angelo D'Alessandro; Craig T Jordan
Journal:  Cell Stem Cell       Date:  2020-08-20       Impact factor: 24.633

5.  Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia.

Authors:  Daniel A Pollyea; Brett M Stevens; Courtney L Jones; Amanda Winters; Shanshan Pei; Mohammad Minhajuddin; Angelo D'Alessandro; Rachel Culp-Hill; Kent A Riemondy; Austin E Gillen; Jay R Hesselberth; Diana Abbott; Derek Schatz; Jonathan A Gutman; Enkhtsetseg Purev; Clayton Smith; Craig T Jordan
Journal:  Nat Med       Date:  2018-11-12       Impact factor: 53.440

6.  Single-Cell RNA-Seq Reveals AML Hierarchies Relevant to Disease Progression and Immunity.

Authors:  Peter van Galen; Volker Hovestadt; Marc H Wadsworth Ii; Travis K Hughes; Gabriel K Griffin; Sofia Battaglia; Julia A Verga; Jason Stephansky; Timothy J Pastika; Jennifer Lombardi Story; Geraldine S Pinkus; Olga Pozdnyakova; Ilene Galinsky; Richard M Stone; Timothy A Graubert; Alex K Shalek; Jon C Aster; Andrew A Lane; Bradley E Bernstein
Journal:  Cell       Date:  2019-02-28       Impact factor: 41.582

7.  High stem cell frequency in acute myeloid leukemia at diagnosis predicts high minimal residual disease and poor survival.

Authors:  Anna van Rhenen; Nicole Feller; Angèle Kelder; August H Westra; Elwin Rombouts; Sonja Zweegman; Marjolein A van der Pol; Quinten Waisfisz; Gert J Ossenkoppele; Gerrit Jan Schuurhuis
Journal:  Clin Cancer Res       Date:  2005-09-15       Impact factor: 12.531

8.  Stem cell gene expression programs influence clinical outcome in human leukemia.

Authors:  Kolja Eppert; Katsuto Takenaka; Eric R Lechman; Levi Waldron; Björn Nilsson; Peter van Galen; Klaus H Metzeler; Armando Poeppl; Vicki Ling; Joseph Beyene; Angelo J Canty; Jayne S Danska; Stefan K Bohlander; Christian Buske; Mark D Minden; Todd R Golub; Igor Jurisica; Benjamin L Ebert; John E Dick
Journal:  Nat Med       Date:  2011-08-28       Impact factor: 53.440

9.  DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia.

Authors:  Maria E Figueroa; Sanne Lugthart; Yushan Li; Claudia Erpelinck-Verschueren; Xutao Deng; Paul J Christos; Elizabeth Schifano; James Booth; Wim van Putten; Lucy Skrabanek; Fabien Campagne; Madhu Mazumdar; John M Greally; Peter J M Valk; Bob Löwenberg; Ruud Delwel; Ari Melnick
Journal:  Cancer Cell       Date:  2010-01-07       Impact factor: 31.743

10.  An LSC epigenetic signature is largely mutation independent and implicates the HOXA cluster in AML pathogenesis.

Authors:  Namyoung Jung; Bo Dai; Andrew J Gentles; Ravindra Majeti; Andrew P Feinberg
Journal:  Nat Commun       Date:  2015-10-07       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.